SCHEMBL23615642

SCHEMBL23615642

O=C(CC1(O)C(=O)N(CCc2c[nH]c3ccccc23)c2ccccc21)c1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ CBX7 O95931 3/20 0.49
▸ CDYL Q9Y232 3/20 0.49
▸ CDY1; CDY1B Q9Y6F8 3/20 0.49
▸ CDYL2 Q8N8U2 2/20 0.49
▸ TP53 P04637 7/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ MAPT P10636 4/20 0.47
▸ MAPK1 P28482 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22761146 1.00 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615673 0.95 CBX7 (0.51) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615751 0.95 CBX7 (0.51) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615744 0.94 TP53 (0.49) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL22761257 0.94 TP53 (0.49) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615771 0.90 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615647 0.90 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ACBX7CDYL
SCHEMBL23615704 0.90 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ATP53SMN1; SMN2
SCHEMBL22761201 0.90 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ATP53SMN1; SMN2
SCHEMBL23615757 0.90 ALDH1A1 (0.55) ALDH1A1MEN1KMT2ACBX7CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634957-B1 NMDA RECEPTOR MODULATORS, COMPOSITIONS COMPRISING SAME AND USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM ADPUERIVITAM (FR) 2021-07-07 — — EP disclosed
Send feedback